Changchun High-Tech Industry (Group) Co., Ltd. (SHE:000661)
China · Delayed Price · Currency is CNY 81.01
-2.37 (-2.84%)
May 20, 2026, 11:25 AM CST
SHE:000661 Revenue
Changchun High-Tech Industry (Group) had revenue of 2.59B CNY in the quarter ending March 31, 2026, a decrease of -13.69%. This brings the company's revenue in the last twelve months to 11.67B, down -12.14% year-over-year. In the year 2025, Changchun High-Tech Industry (Group) had annual revenue of 12.08B, down -10.27%.
Revenue (ttm)
11.67B
Revenue Growth
-12.14%
P/S Ratio
2.87
Revenue / Employee
1.16M
Employees
10,080
Market Cap
33.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.08B | -1.38B | -10.27% |
| Dec 31, 2024 | 13.47B | -1.10B | -7.55% |
| Dec 31, 2023 | 14.57B | 1.94B | 15.35% |
| Jan 1, 2023 | 12.63B | 1.88B | 17.50% |
| Jan 1, 2022 | 10.75B | 2.17B | 25.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Resources Sanjiu Medical & Pharmaceutical | 32.88B |
| Humanwell Healthcare (Group) | 23.93B |
| Beijing Tongrentang | 16.64B |
| Livzon Pharmaceutical Group | 11.71B |
| Zhejiang Huahai Pharmaceutical | 8.55B |
| Shijiazhuang Yiling Pharmaceutical | 7.91B |
| Dong-E-E-Jiao | 6.80B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
Changchun High-Tech Industry (Group) News
- 27 days ago - Changchun High-Tech Industry (Group) Annual report: Q4 2025 - Filings
- 4 weeks ago - Changchun High-Tech Industry (Group) Quarterly report: Q1 2026 - Filings
- 5 months ago - Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion - South China Morning Post
- 7 months ago - Changchun High-Tech Industry (Group) Quarterly report: Q3 2025 - Filings
- 9 months ago - Changchun High-Tech Industry (Group) Quarterly report: Q2 2025 - Filings